comprehensive -WSS

comprehensive

author：hotspot 2025-09-02 08:22:01 - browse：2

President Biden's White House announced the first 10 medicines that will be up first in its new drug price negotiation program. Anna Moneymaker/Getty Images

WASHINGTON — Medicare on Tuesday announced it will negotiate prices for 10 drugs, including major blood thinners and diabetes medications, in the first round of its negotiation program created in Democrats’ drug pricing reform law.

The drugs include Bristol Myers Squibb’s blood thinner Eliquis, Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, Johnson & Johnson’s blood thinner Xarelto, Merck’s diabetes drug Januvia, AstraZeneca’s diabetes drug Farxiga, Novartis’ heart failure treatment Entresto, Amgen’s rheumatoid arthritis drug Enbrel, Johnson & Johnson and AbbVie’s blood cancer treatment Imbruvica, J&J’s anti-inflammatory medicine Stelara, and Novo Nordisk insulins that go by names including Fiasp and NovoLog.

The new prices will be announced on Sept. 1, 2024, and will go into effect on Jan. 1, 2026. The drugs were chosen from a list of 50 treatments that cost Medicare’s pharmacy drug benefit the most money. The selected medicines cost Medicare more than $50 billion and made up 20% of the Medicare program’s pharmacy drug costs over a one-year period, the Department of Health and Human Services said. (Read more here about the winners and losers of the selection.)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

focus

WSS

How digital therapeutics firms are pivoting after Pear's bankruptcy

Radiation, mainstay of cancer treatment, begins a fade

Departing Stanford president retracts two papers

Why more medical students aren't specializing in primary care

Study finds new variant for Parkinson’s in African populations

How a symptom of dementia informs our understanding of creativity

entertainment

comprehensive

Wikipedia

In Memoriam: Notable people who died in 2023

2024 GOP presidential candidates spar over abortion in debate

Novavax promises a turnaround & Lilly roils the obesity market

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Psychedelics group wrestles with new pharma identity

EU regulator recommends expanding Mounjaro approval to obesity

Duchenne breakthrough therapy leaves behind pioneering families

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Jerome Adams on the need for new antivirals for Covid

Prior authorization will have to move faster under new Biden rule

focus

Apellis safety probe of eye disease drug centers on injection needle

The surgeon had a dilemma only a Nazi medical text could resolve

Medicare explains how it will choose drugs for negotiation

Winners, losers from Medicare’s list of drugs subject to price talks

Winners, losers from Medicare’s list of drugs subject to price talks

Complete sequence of Y chromosome published for first time

focus

focus

knowledge

Wikipedia